Fracture risk, osteoporosis and osteopenia prevention and treatment strategies for adults over 40, especially postmenopausal women

Midlife Bone & Osteoporosis Care

Midlife and beyond represent a critical period for skeletal health, particularly for adults over 40 and postmenopausal women who face escalating risks of osteoporosis, osteopenia, and fragility fractures. Recent advances deepen our understanding of the multifaceted drivers of bone fragility—ranging from hormonal fluctuations and medication impacts to lifestyle, nutrition, and emerging biological influences such as the gut microbiome. These insights are reshaping prevention, screening, and treatment strategies, emphasizing a holistic and personalized approach to maintaining bone integrity and reducing fracture risk.

Rising Fracture Risk After 40: A Complex Interplay of Hormonal, Medication, and Environmental Factors

The postmenopausal period remains the most vulnerable phase for accelerated bone loss, primarily due to estrogen deficiency. This hormonal decline disrupts the delicate balance of bone remodeling by favoring osteoclastic resorption over osteoblastic formation, leading to deterioration of trabecular bone and increased fragility, especially at the hip, spine, and wrist.

New evidence highlights several intertwined contributors to fracture risk:

Hormonal Changes and Gut Microbiome Interactions
Beyond the well-established role of estrogen decline, emerging research reveals that perimenopausal shifts in the gut microbiota may influence bone metabolism. A recent study published by NIH’s PMC highlights how nutritional compounds—polyphenols, dietary fibers, and soy isoflavones—interact with the microbiome to modulate systemic inflammation and bone health during this transition. These findings open new avenues for therapeutic targeting of the gut-bone axis in midlife women.
Medication-Related Bone Effects
- GLP-1 Receptor Agonists (GLP-1 RAs): Widely prescribed for type 2 diabetes and obesity, agents like Ozempic and Wegovy have been newly associated with an increased 5-year risk of osteoporosis and fractures. The American Academy of Orthopaedic Surgeons (AAOS) now recommends routine bone mineral density (BMD) monitoring in patients on GLP-1 RAs to detect early skeletal compromise.
- Cancer Therapies: Chemotherapy and radiation, particularly in breast cancer survivors, accelerate bone loss through gonadotoxicity and systemic inflammation. Integrated bone health management is increasingly recognized as essential in oncology survivorship care.
- Prior Fracture History: Consistent with prior knowledge, a history of fragility fractures remains one of the strongest predictors of future fractures, underscoring the need for vigilant surveillance and intervention.
Lifestyle and Environmental Influences
- Diets high in ultra-processed foods continue to negatively affect bone quality by promoting nutritional deficiencies and low-grade systemic inflammation.
- Novel environmental concerns include the potential impact of rising atmospheric CO₂ levels on bone mineralization, suggesting climate-related factors may subtly exacerbate skeletal vulnerability and warrant further research.
- Smoking and alcohol consumption persist as modifiable risk factors. Notably, recent data report that 40–71% of midlife women experience arthralgia, with smoking intensifying joint pain and potentially undermining physical activity adherence critical for bone health.

Enhanced Screening and Risk Assessment: Toward Precision Medicine

Dual-energy X-ray absorptiometry (DXA) remains the gold standard for BMD screening, but updated guidelines expand its application:

Routine screening for all postmenopausal women at menopause or earlier if risk factors exist
Inclusion of patients on GLP-1 RAs and those undergoing cancer therapies due to their elevated fracture risk profiles
Targeted screening for individuals with prior fragility fractures or significant clinical risk factors

In parallel, fracture risk calculators like FRAX have been refined to incorporate additional clinical modifiers, including medication exposure and detailed fracture history, enabling more personalized risk stratification and informed treatment decisions.

Comprehensive Prevention: Integrating Exercise, Nutrition, and Lifestyle Modification

A holistic approach to fracture prevention emphasizes osteogenic exercise, optimized nutrition, and lifestyle adjustments that support both bone and muscle health.

Osteogenic and Functional Exercise

Weight-bearing and resistance training remain foundational, stimulating bone formation and improving skeletal strength. Innovations like OsteoStrong, which delivers osteogenic loading through specialized equipment, show promise as adjuncts.
Accessibility is key: simple, equipment-free activities such as walking, stair climbing, and balance exercises are strongly encouraged for their broad musculoskeletal benefits and fall risk reduction.
Maintaining muscle mass is essential, given its role in supporting bone and preventing falls. Adequate protein intake and emerging supplements like creatine have shown potential in preserving muscle mass and indirectly benefiting bone health.
Addressing arthralgia, especially common in midlife women and worsened by smoking, through cessation programs and tailored physical activity regimens enhances exercise adherence and functional capacity.

Nutrition: Expanding Beyond Calcium and Vitamin D

While calcium and vitamin D remain pillars of bone health, new research underscores the importance of additional nutrients and dietary patterns:

Vitamin K is crucial for activating osteocalcin, a protein vital for bone matrix formation and mineralization.
High-quality protein supports both muscle and bone, especially important during aging and weight management. Recent nutrition science stresses even distribution of protein intake throughout the day to maximize musculoskeletal benefits.
Soy isoflavones, natural phytoestrogens, interact with estrogen receptors as selective modulators, offering a promising alternative or adjunctive strategy to mitigate menopausal bone loss while minimizing risks associated with conventional hormone therapy. A recent article titled “Estrogen Receptor–Phytoestrogen Interactions in Health and Aging” elaborates on these mechanisms and their therapeutic potential.
Reducing ultra-processed food consumption in favor of whole, nutrient-dense options (leafy greens, fortified dairy or alternatives, nuts, seeds, and oily fish with edible bones) helps reduce systemic inflammation and improve nutrient bioavailability.
Combatting nutrition misinformation remains vital. Initiatives like “EP. 15 - Misinformation in Nutrition: Separating Fact From Fiction with Rachel Laster, RDN” provide clear, evidence-based guidance to empower patients and clinicians alike.

Pharmacological Treatments: Tailoring Therapies to Individual Risk Profiles

Current pharmacological options include:

Antiresorptive agents:
- Bisphosphonates (e.g., alendronate, zoledronic acid) inhibit osteoclast activity and reduce bone resorption.
- Denosumab, a monoclonal antibody targeting RANKL, effectively lowers bone turnover.
- Selective Estrogen Receptor Modulators (SERMs), such as raloxifene, confer bone protection with some estrogenic effects, offering alternatives for patients contraindicated for hormone replacement therapy (HRT).
Anabolic therapies:
- Parathyroid hormone (PTH) analogues stimulate new bone formation and improve bone quality.
- Emerging anabolic agents are under investigation, with promising clinical trial results but pending broader validation and guideline inclusion.

Pharmacotherapy selection must be individualized, especially for patients with prior fractures, cancer survivors, or those on GLP-1 RAs, with ongoing monitoring for efficacy and safety.

Special Populations: Cancer Survivors and GLP-1 RA Users

Cancer Survivors:
The compounded bone loss from cancer treatments necessitates multidisciplinary management involving oncologists, endocrinologists, and rehabilitation specialists. Proactive BMD monitoring and targeted rehabilitative interventions are crucial components of survivorship care plans.
GLP-1 RA Users:
Given their association with increased fracture risk, these patients require baseline and periodic DXA assessments, alongside counseling on bone-supportive lifestyle measures and prompt management of emerging bone fragility.
Postmenopausal Hormonal Management:
Hormone replacement therapy remains a valuable option for bone preservation in suitable candidates, but requires individualized risk-benefit evaluation considering cardiovascular, oncologic, and skeletal factors.

Empowering Patients Through Education and Shared Decision-Making

Sustainable improvements in bone health depend heavily on patient engagement and education. Resources such as “Osteoporosis Alert! Bone-Strengthening Secrets Every Woman MUST Know” and “7 Best Treatments for Osteopenia: Natural Remedies and Supplements” provide accessible, evidence-based information.

Clinician-led educational content, including “Meet the Doctor – Preventing and Treating Osteoporosis” with Dr. Courtney Stull, fosters informed shared decision-making, improving treatment adherence and clinical outcomes.

Additionally, campaigns promoting “Find Nutrition Advice Backed by Science” help patients navigate the often conflicting landscape of dietary guidance, counteracting misinformation and supporting evidence-based choices.

Integrating Weight Management and Longevity Strategies

Recent research emphasizes the importance of adequate and well-distributed protein intake in women over 40 to support lean muscle mass, enhance satiety, and maintain skeletal strength during weight management efforts.

Combined with functional exercises that require no gym equipment, such as balance and mobility training, this approach enhances musculoskeletal resilience, reduces fall and fracture risk, and promotes healthy aging.

Summary and Clinical Implications

For adults over 40—especially postmenopausal women—midlife is a pivotal window for implementing comprehensive, multidimensional bone health strategies:

Routine DXA screening and refined fracture risk assessments that include medication exposures (e.g., GLP-1 RAs, cancer therapies) and fracture history
Vigilant monitoring and management of bone impacts from emerging medication risks
Holistic lifestyle approaches emphasizing:
- Osteogenic and resistance exercises
- Nutritionally balanced diets rich in calcium, vitamin D, vitamin K, high-quality protein, and phytoestrogens
- Minimization of ultra-processed foods, smoking cessation, and alcohol moderation
Targeted use of evidence-supported supplementation and pharmacotherapy tailored to individual risk profiles
Enhanced patient education and shared decision-making to foster adherence and optimize outcomes

Conclusion

Advancements in understanding fracture risk and bone health after age 40 underscore the necessity of a personalized, integrative approach. By incorporating cutting-edge science—from microbiome influences to medication effects—functional fitness, nutritional optimization, and patient empowerment, clinicians and patients can collaboratively reduce the burden of osteoporosis and osteopenia. This comprehensive strategy supports skeletal strength and quality of life well into later years, transforming midlife from a period of vulnerability into an opportunity for longevity and resilience.

Sources (27)